Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? [Clinical Sciences]
Conclusions—There may be an obesity paradox in atrial fibrillation patients, particularly for all-cause and cardiovascular death outcomes. An obesity paradox was also evident for stroke/systemic embolic event outcome in NOAC trials, with a treatment effect favoring NOACs over warfarin for both efficacy and safety that was significant only for normal weight patients.
Source: Stroke - Category: Neurology Authors: Marco Proietti, Elisa Guiducci, Paola Cheli, Gregory Y.H. Lip Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Obesity, Anticoagulants, Quality and Outcomes Original Contributions Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Eating Disorders & Weight Management | Heart | Obesity | Stroke | Study | Vitamins | Warfarin